Blood cell collection could open door to CAR T-Cell therapy for leukemia and lymphoma patients
NCT ID NCT03226704
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 3 times
Summary
This study collects white blood cells from 120 people aged 3 to 65 with leukemia or lymphoma that hasn't been cured by standard treatments. The cells are gathered through a procedure called leukapheresis, then processed and frozen for future use in CAR T-cell therapy. The goal is to identify patients early who could benefit from this advanced treatment and have their cells ready when needed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Leukapheresis
- What this could lead to
- If successful, this study could help more people with hard-to-treat blood cancers get CAR T-cell therapy sooner.
- What could go wrong
- This is an early collection study, not a treatment trial. The cells may not be used if the patient's condition changes or if they don't qualify for a future CAR T-cell study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Could muscle loss predict blood cancer outcomes?
- Can an immune booster outsmart brain lymphoma?
- Can a Tumor's DNA guide better cancer care for kids?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?